RNA 49.50 Avidity Biosciences, Inc.
| Range: | 4.825-49.41 | Vol Avg: | 1418901 | Last Div: | 0 | Changes: | 2.38 |
| Beta: | 0.89 | Cap: | 5.46B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Jun 12 2020 | Empoloyees: | 253 | ||
| CUSIP: | 05370A108 | CIK: | 0001599901 | ISIN: | US05370A1088 | Country: | US |
| CEO: | Ms. Sarah Boyce | Website: | https://www.aviditybiosciences.com | ||||
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Stock Details
RNA 59
Goldman Sachs Starts Avidity Biosciences (RNA) at Buy
Corinne Johnson·Tue Sep 24 2024
Goldman Sachs
RNA 50
Wells Fargo Reiterates Overweight Rating on Avidity Biosciences (RNA)
Yanan Zhu·Wed Jun 12 2024
Wells Fargo
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow